Fact based stock research
BioAlliance (ENXTPA:ONXEO)


BioAlliance stock research in summary

bioalliancepharma.com


BioAlliance shares have a BUY rating. They are good value and show above average growth, but are riskily financed. We recommend buying and holding BioAlliance shares.


Latest Obermatt Ranks


Country France
Industry Biotechnology
Index CAC All
Size class X-Small

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock



Research History: BioAlliance

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
50
46
81
83
STOCK GROWTH RANKS
1
40
50
65
STOCK SAFETY RANKS
48
42
74
43
COMBINED STOCK RANKS
20
29
86
82

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is BioAlliance in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of BioAlliance; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
12
55
44
81
PROFIT GROWTH
25
25
25
84
STOCK RETURNS
18
44
86
13
CONSOLIDATED RANK: GROWTH
1
40
50
65

Financial reporting date of Growth Rank: 31-Dec-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of BioAlliance.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
60
65
86
58
REFINANCING
27
30
33
26
LIQUIDITY
59
40
41
59
CONSOLIDATED RANK: SAFETY
48
42
74
43

Financial reporting date of Safety Rank: 31-Dec-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of BioAlliance and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for BioAlliance from June 8, 2018.